Peetz Christopher 4
4 · Mirum Pharmaceuticals, Inc. · Filed Aug 8, 2025
Insider Transaction Report
Form 4
Peetz Christopher
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Sale
Common Stock
2025-08-07$55.25/sh−40,000$2,210,040→ 138,641 total - Exercise/Conversion
Common Stock
2025-08-07$2.94/sh+40,000$117,440→ 178,641 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-08-07−40,000→ 198,487 totalExercise: $2.94Exp: 2029-03-11→ Common Stock (40,000 underlying)
Holdings
- 208,570(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on November 22, 2024.
- [F2]The weighted average sale price for the transaction reported was $55.251022, and the range of prices were between $55.25 and $55.485. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The stock option is fully vested.